These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26169690)

  • 1. DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer.
    Stone A; Zotenko E; Locke WJ; Korbie D; Millar EK; Pidsley R; Stirzaker C; Graham P; Trau M; Musgrove EA; Nicholson RI; Gee JM; Clark SJ
    Nat Commun; 2015 Jul; 6():7758. PubMed ID: 26169690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues.
    Shenker NS; Flower KJ; Wilhelm-Benartzi CS; Dai W; Bell E; Gore E; El Bahrawy M; Weaver G; Brown R; Flanagan JM
    BMC Cancer; 2015 May; 15():337. PubMed ID: 25927974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
    Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
    Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer.
    Zhao H; Ou-Yang F; Chen IF; Hou MF; Yuan SS; Chang HL; Lee YC; Plattner R; Waltz SE; Ho SM; Sims J; Wang SC
    Neoplasia; 2010 Mar; 12(3):214-23. PubMed ID: 20234815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
    Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The promoter C specific ERalpha isoform is associated with tamoxifen outcome in breast cancer.
    Amaral S; Schroth W; Kugler S; Fritz P; Simon W; Brauch H
    Breast Cancer Res Treat; 2009 Nov; 118(2):323-31. PubMed ID: 19011961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ESR1 and PGR gene promoter methylation and correlations with estrogen and progesterone receptors in ductal and lobular breast cancer.
    Medina-Jaime AD; Reyes-Vargas F; Martinez-Gaytan V; Zambrano-Galvan G; Portillo-Delcampo E; Burciaga-Nava JA; Reyes-Romero M; Sifuentes-Alvarez A
    Asian Pac J Cancer Prev; 2014; 15(7):3041-4. PubMed ID: 24815444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptional coregualtor NUPR1 maintains tamoxifen resistance in breast cancer cells.
    Wang L; Sun J; Yin Y; Sun Y; Ma J; Zhou R; Chang X; Li D; Yao Z; Tian S; Zhang K; Liu Z; Ma Z
    Cell Death Dis; 2021 Feb; 12(2):149. PubMed ID: 33542201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene.
    Chang HG; Kim SJ; Chung KW; Noh DY; Kwon Y; Lee ES; Kang HS
    J Mol Med (Berl); 2005 Feb; 83(2):132-9. PubMed ID: 15536519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.
    Jeselsohn R; Buchwalter G; De Angelis C; Brown M; Schiff R
    Nat Rev Clin Oncol; 2015 Oct; 12(10):573-83. PubMed ID: 26122181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.
    Merenbakh-Lamin K; Ben-Baruch N; Yeheskel A; Dvir A; Soussan-Gutman L; Jeselsohn R; Yelensky R; Brown M; Miller VA; Sarid D; Rizel S; Klein B; Rubinek T; Wolf I
    Cancer Res; 2013 Dec; 73(23):6856-64. PubMed ID: 24217577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
    Kim SS; Lee MH; Lee MO
    Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer.
    Nielsen KV; Ejlertsen B; Müller S; Møller S; Rasmussen BB; Balslev E; Lænkholm AV; Christiansen P; Mouridsen HT
    Breast Cancer Res Treat; 2011 Jun; 127(2):345-55. PubMed ID: 20556506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes.
    Yates ME; Waltermire H; Mori K; Li Z; Li Y; Guzolik H; Wang X; Liu T; Atkinson JM; Hooda J; Lee AV; Oesterreich S
    Endocrinology; 2024 Aug; 165(10):. PubMed ID: 39207954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor mutations and their role in breast cancer progression.
    Alluri PG; Speers C; Chinnaiyan AM
    Breast Cancer Res; 2014 Dec; 16(6):494. PubMed ID: 25928204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone receptor-positive invasive lobular and ductal carcinoma of the breast have comparable hormone receptor expression levels both if detected by screening and clinically.
    Ravaioli A; Falcini F; Bucchi L
    Breast Cancer Res Treat; 2018 Feb; 167(3):817-818. PubMed ID: 29027616
    [No Abstract]   [Full Text] [Related]  

  • 19. The Role of ESR1 Gene Polymorphic Markers in the Development of Breast Cancer and Resistance to Tamoxifen Therapy.
    Lukina SS; Burdennyy AM; Zavarykina TM; Riabchikov DA; Kazubskaya TP; Kruglova MP; Loginov VI
    Bull Exp Biol Med; 2021 Jan; 170(3):350-355. PubMed ID: 33452979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers.
    Ng CW; Tsang YTM; Gershenson DM; Wong KK
    Br J Cancer; 2024 May; 130(11):1875-1884. PubMed ID: 38582811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.